Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 5/20 | 0.34 |
| ▸ | CTSL | P07711 | 4/20 | 0.34 |
| ▸ | CTSS | P25774 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486478 | 0.89 | CTSL (0.41) | EPHX2NPC1RAB9ASMN1; SMN2CTSK | |
| SCHEMBL6486966 | 0.89 | HPGD (0.39) | EPHX2NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL6485378 | 0.86 | EPHX2 (0.38) | EPHX2NPC1RAB9ASMN1; SMN2CTSK | |
| SCHEMBL6482606 | 0.85 | RAB9A (0.35) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL6476739 | 0.83 | CCR2 (0.37) | EPHX2NPC1RAB9ASMN1; SMN2CTSK | |
| SCHEMBL6475732 | 0.81 | RAB9A (0.35) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL6475024 | 0.80 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL6476626 | 0.79 | ESRRG (0.34) | NPC1RAB9ACTSKCTSLCTSS | |
| SCHEMBL6590719 | 0.79 | — | — | |
| SCHEMBL6595810 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | claimed |
| EP-1178986-B1 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LTD (GB) | 2004-02-25 | — | — | EP | claimed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | claimed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1178986-B1 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | EPHX2 2750/4885NPC1 1874/4885RAB9A 2562/4885 |
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | EPHX2 2750/4885NPC1 1874/4885RAB9A 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.